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PHASE II TRIAL TO EVALUATE THE ACTIGAIT IMPLANTED DROP-FOOT 
STIMULATOR IN ESTABLISHED HEMIPLEGIA
Jane Burridge3, Morten Haugland1, Birgit Larsen1,2, Ruth M. Pickering3, Niels Svaneborg4, Helle 
K. Iversen5, P. Brøgger Christensen6, Jens Haase2, Jannick Brennum5 and Thomas Sinkjaer2
From the 1Neurodan A/S, Aalborg, 2University of Aalborg, Aalborg, Denmark, 3University of Southampton, Highfield, 
Southampton, UK, 4Brønderslev Neuro Rehabiliteringscenter, Sygehus Vendsyssel, Brønderslev, 5Glostrup Hospital, 
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Objective: To evaluate a selective implantable drop foot sti-
mulator (ActiGait) in terms of effect on walking and safety.
Design: A phase II trial in which a consecutive sample of 
participants acted as their own controls.
Subjects: People who had suffered a stroke at least 6 months 
prior to recruitment and had a drop-foot that affected 
walking were recruited from 3 rehabilitation centres in Den-
mark.
Methods: Stimulators were implanted into all participants. 
Outcome measures were range of ankle dorsiflexion with sti-
mulation and maximum walking speed and distance walked 
in 4 minutes. Measurements were applied before implan-
tation, at 90 days and at a long-term follow-up assessment. 
Changes over time and with and without stimulation are re-
ported. Safety was evaluated by nerve conduction velocity 
and adverse events.
Results: Fifteen participants were implanted and 13 com-
pleted the trial. Long-term improvements were detected in 
walking speed and distance walked in 4 minutes when sti-
mulated, and the orthotic effect of stimulation showed statis-
tically significant improvement. The device did not compro-
mise nerve conduction velocity and no serious device-related 
adverse events were reported. Technical problems were 
resolved by the long-term follow-up assessment at which 
further improvement in walking was observed. 
Conclusion: This trial has evaluated the safety and perfor-
mance of the device, which was well accepted by patients 
and did not compromise safety.
Key words: electrical stimulation, implanted electrodes, rehabi-
litation, stroke and gait.
J Rehabil Med 2007; 39: 212–218
Correspondence address: Jane Burridge, SOHPRS, University 
of Southampton, Highfield, Southampton SO17 1BJ, UK. 
E-mail: jhb1@soton.ac.uk
Submitted May 2, 2006; accepted October 12, 2006 
INTRODUCTION
Drop-foot is a common problem following stroke, caused by a 
combination of weak anterior tibial muscles and calf spasticity 
or ankle stiffness (1), in which the individual is unable to lift 
the toes clear of the ground effectively during the swing phase 
of walking. It affects between 20% and 30% of patients un-
dergoing rehabilitation (2) and is associated with an increased 
risk of falling, increased effort of walking and, in consequence, 
reduced mobility and independence.
The conventional approach to management of drop-foot is 
through the use of an orthosis, but recently functional electri-
cal stimulation has been shown to be an effective alternative, 
with statistically and clinically significant improvements in 
walking speed and effort (3–6). A study to evaluate a surface 
drop-foot system (used by over 2000 patients, mainly in the 
UK) from the patient’s perspective identified that the main 
problems with the system were: inconvenience of the external 
components, especially in donning and doffing; positioning the 
self-adhesive electrodes in the correct place on the leg; and 
irritation of the skin under the electrodes (7). Although these 
problems can potentially be overcome by implanted systems, 
previous systems developed in the 1970s and 1980s (8–10) 
did not provide selective stimulation of nerve fascicles to 
achieve a balance between inversion and eversion of the ankle 
necessary for normal walking and were in some cases rejected 
by patients because they caused excessive ankle eversion. 
More recently, preliminary studies have been reported of a 2-
channel implanted system that uses electrodes located under 
the epineurium of the deep and superficial peroneal nerves. 
Improvement in walking speed of 10% and 44% was shown 
in 2 participants (11) and good selectivity in 10 participants, 
identified as ankle dorsiflexion, plantarflexion, inversion and 
eversion torques measured in a specially designed rig (12). The 
effect of the system on walking with these 10 participants was 
not reported. The first prototype of the ActiGait system was 
implanted in 3 people in 1999, and has since undergone some 
design revisions. The objectives of this trial were to evaluate 
the performance and safety of the device.
METHOD
Institutional review and ethical approval was granted for the trial (VN 
2002/56mch), which was performed according to the Helsinki Declaration 
(1983 revision). This work was funded by Neurodan A/C Denmark.
ActiGait drop-foot stimulator
The ActiGait (Fig. 1) is an implantable drop-foot stimulator that 
allows independent adjustment of stimulation output from each of 4 
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channels via a single nerve cuff. The system comprises an implant, a 
control unit, a heel switch that triggers the initiation and termination 
of each stimulation sequence, and a clinical station. The implant cuff 
is placed around the common peroneal nerve, just proximal to its 
bifurcation into the deep and superficial branches to tibialis anterior 
and the peronei muscles. At this point the nerve fascicles have become 
spatially organized within the nerve, so that each set of electrodes 
within the cuff is adjacent to fascicles travelling to different motor 
points or muscles; thus activating slightly different movements. A cable 
from the nerve cuff travels subcutaneously to the receiver positioned 
laterally on the thigh. A transmitter coil (antenna) is positioned on 
the skin over the receiver and is hard-wired externally to the control 
unit worn on the belt.
The user is able to switch stimulation on and off and make adjust-
ments to the level of stimulation via the control unit. Stimulation is 
activated by a radio frequency wireless signal from a footswitch that 
can either be worn in the shoe, or within a sock to allow bare-foot 
walking. The antenna, which is attached to the skin on the upper thigh 
over the receiver, is easily reached by the patient without bending. 
Stimulation parameters are set up within the control unit via the clinical 
station – a standard computer (PC) and graphical software program. 
The clinician can control frequency, stimulation intensity, ramping and 
timing of the stimulation channels and can test the effect of individual 
and combined channels of stimulation.
Trial design
A consecutive sample of participants, recruited from 3 stroke rehabi-
litation centres in Denmark, acted as their own controls. Participants 
were assessed at baseline, at a follow-up assessment 90 days post-
implantation and at a final assessment 15 months after the first parti-
cipant was implanted. All assessments took place in the rehabilitation 
centres where the participants were recruited and were conducted by 
the local physiotherapists who had undergone training sessions (ap-
proximately 8 hours) in programming the ActiGait and performing 
the assessments.
Eligibility criteria
All participants gave written informed consent, were over the age of 
18 years, and had a drop-foot following a stroke at least 6 months prior 
to recruitment. Drop-foot was defined as: “lacking ability to obtain 
normal heel contact during gait which can be corrected by electrical 
stimulation of the peroneal nerve”. All participants had at least 30° 
of passive ankle movement and were able to stand upright with heels 
touching the floor when the hip and knee were in a neutral position. 
Participants who were unable to walk 100 metres without stopping 
prior to their stroke, who walked faster than 1.2 metres/second (m/s), 
or who were unable to stand without an ankle foot orthosis at the time 
of screening, were excluded. Further exclusion criteria were: uncon-
trolled epilepsy; unstable diagnosed psychological conditions; and 
the presence of other implanted devices such as a cardiac pacemaker. 
Following screening there was an interval of at least 5 weeks before 
the surgical procedure. Participants understood that they were free to 
withdraw from the trial at any time prior to or after implantation.
Surgical procedure
Implantation was performed under spinal anaesthetic in 8 participants, 
and general anaesthetic in 7. The common peroneal nerve was expo-
sed through a longitudinal incision along the tendon of the biceps 
femoris muscle and a second incision was made on the lateral side of 
the femur, posterior to the location for the stimulator body. The cuff 
electrode was placed around the motor part of the common peroneal 
nerve and the system was tested before the cuff sutures were closed. 
The stimulator body was secured with 1 or 2 sutures to the lateral 
femoral fascia and the skin incisions closed in 2 layers. The mean 
time for surgery was 38 minutes.
Outcome measures
Outcome measures were distance walked in 4 minutes, maximum 
walking speed and range of ankle dorsiflexion. Range of ankle dorsi-
flexion was measured by electro-goniometer (Neurodan model 01, 
Neurodan A/S, Aalborg, Denmark), with stimulation and without 
voluntary assistance in supine lying and sitting at the 90 day assess-
ment. Maximum movement in response to 3 bursts of stimulation 
was recorded. Distance walked, as a measure of endurance, is an 
effective measure of recovery following stroke (13, 14) and speed 
of walking is a simple measure of walking that correlates well with 
other walking parameters (15). In this trial, participants walked for 4 
minutes around a 20 metre figure-of-eight track marked on the floor 
and were given at least 15 minutes rest between tests. Total distance 
walked in 4 minutes and maximum walking speed over one complete 
circuit was recorded. Walking tests were recorded on video-tape for 
independent verification. Two sets of baseline walking data were 
Fig. 1. The ActiGait system.
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recorded pre-implantation, one week apart, the first enabled partici-
pants to become accustomed to the procedure; the second was used in 
the analysis. Follow-up tests were performed stimulated (S) and not 
stimulated; order of tests was randomized by asking participants to 
choose 1 of 2 opaque sealed envelopes each containing a card with the 
words either: “with stimulation” or “without stimulation” to indicate 
which test was performed first. 
In addition to the outcome measures, participants were asked at each 
assessment about how much they used of the system and any problems or 
benefits they had experienced. Comments were documented verbatim.
To evaluate safety, all adverse events were documented. Because of 
the potential risk of nerve damage due to the cuff, nerve conduction 
velocities were measured (16) pre-implantation and no less than 90 
days post-implantation in the deep branches of the peroneal nerve 
to the extensor digitorum brevis, tibialis anterior muscles and the 
superficial branch. 
Statistical analysis of the effect of stimulation
Using an intention to treat (ITT) approach to analysis, all cases for 
which outcome data were available were included in the analysis, 
including 3 participants whose devices were not working optimally 
at the time of assessment. Assessments were not performed with par-
ticipants whose devices required re-implantation and one participant 
whose medical condition had deteriorated and was unable to complete 
the assessments. Details of problems encountered with the device and 
consequent availability of assessment data are shown in Fig. 2.
Characteristics of the trial participants at baseline and distribution of 
ankle range of movement were summarized using descriptive statistics. 
The mean standard deviation (SD) and range for walking test data 
amongst all participants included at each assessment are presented. 
The long-term effect of stimulation was based on the comparison of 
measurements made with stimulation at the 90 day and final assess-
ments, and measurements made without stimulation at baseline and is 
the most important assessment of benefit to participants. Although we 
did not expect to see long-term therapeutic benefits in this group of 
chronic stroke patients, long-term therapeutic effects were measured 
based on the comparison of measurements made without stimulation 
at the 90 day and final assessment, and measurements made without 
stimulation at baseline. Finally, the short-term orthotic effect of sti-
mulation was based on the comparison of measurements made with 
and without stimulation at each follow-up assessment. Comparisons 
are summarized in Fig. 3. Long-term, therapeutic and orthotic effects 
were estimated as the mean change in the relevant test values amongst 
participants who were included at both assessments involved, and 
95% confidence intervals around mean changes were calculated. The 
significance of the effects was assessed using paired t-tests, and be-
cause comparisons were made at 2 time points (90 days and the final 
assessment) they were judged significant at the 5% level if the p value 
was less than the Bonferroni corrected value of 0.025.
RESULTS
Recruitment and progress of participants through the trial 
Recruitment and progress of participants through the trial 
are summarized in Fig. 2. Fifteen participants underwent im-
plantation surgery. The 90 day assessment took place within 
87 and 94 days post-implantation, with the exception of one 
subject whose assessment was delayed until 114 days. The 
final assessment, took place between 6 and 15 months post-
implantation (mean (SD): 11.6 (3.6) months).
Baseline characteristics of the 15 participants who were 
implanted with the device are presented in Table I.
The effect of stimulation on ankle angle is presented in 
Table II. For all participants, stimulation resulted in ankle 
dorsiflexion, which was on average just over 20° in both lying 
and sitting.
During the course of the trial, 4 participants experienced pro-
blems with the system that were found to be due to the nerve cuff 
being too large. The protocol for determining cuff size was there-
fore amended and 3 participants underwent re-implantation with 
smaller cuffs between the 90 day and the final assessment. Two 
of the 3 participants were not included at the 90 day assessment, 
but re-entered at the final assessment; one was included at the 90 
day assessment before re-implantation and at the final assessment 
after re-implantation. The fourth participant, included in the 90 
day assessment, was still awaiting re-implantation surgery at 
the final assessment. At the 90 day assessment, 3 participants 
Fig. 3. Assessment scheme, showing what comparisons were made with 
and without stimulation at each assessment.
(S)
(NS)
Fig. 2. Progress of participants through the trial. 1Not included in the 
final assessment.
1
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day assessment, and 13 at the final assessment). Table IV shows 
the long-term and long-term therapeutic effects of using sti-
mulation, respectively, at 90 days, and at the final assessment, 
compared with baseline. Effects are calculated using data only 
from participants assessed at both time points.
Comparisons of maximum walking speed and distance 
walked measured at the 90 day and final assessments with 
stimulation, with values measured at baseline, showed a mean 
improvement at both time points (Table IV). At 90 days im-
provements were not significant, but at the final assessment 
max speed showed a statistically significant improvement by 
virtue of its p-value falling below the Bonferroni corrected 
level of 0.025. Overall, there was a 19% improvement in 
maximum walking speed at the final assessment measured 
with stimulation. Although there was a trend towards an in-
crease in both distance walked and maximum walking speed 
measured without stimulation at the final assessment compared 
with baseline (the therapeutic effect) this was not significant 
(Table IV). Table IV also presents orthotic effects, comparing 
walking with and without stimulation at each time-point. There 
were significant orthotic effects for both walking parameters 
at the 90 day assessment. At the final assessment there was a 
trend to greater orthotic effect than at the 90 day assessment, 
though the orthotic effect on distance walked did not achieve 
statistical significance.
At both the 90 day and long-term follow-up assessments, 11 
of the 13 (91%) participants reported using the system everyday 
and one between 3 and 6 days per week.
Safety
No adverse events were reported during surgery. In 2 cases 
minor wound infections required treatment with antibiotics and 
Table II. Range of ankle joint movement (degrees) measured in lying 
and sitting when stimulation at the 90 day assessment: n = 13.
Range of ankle 
movement Lying Sitting
Mean (SD)
Min to max
95% CI for the mean
24.2 (11.3)
7–47
(17.4, 31.0)
22.5 (12.3)
5–47
(16.7, 29.7)
CI: confidence interval; SD: standard deviation.
Table I. Baseline characteristics of the 15 participants who were 
implanted with the device. 
Characteristics
Gender n (%)
Female
Male
4 (27)
11 (73)
Age (years (y) and months (m)) 
Mean (SD)
Min to max
56 y 10 m (7 y 7 m)
46–68
Height (cm)
Mean (SD)
Min to max
172.6 (8.6)
160–187
Weight (kg) 
Mean (SD)
Min to max
77.2 (12.9)
54–110
Blood pressure (diastolic/systolic) (mmHg)
Mean (SD)
Min to max
143/86 (20/5)
120/80 – 176/95
Resting heart rate (bpm) 
Mean (SD)
Min to max
73 (9.8)
60–92
Side of hemiplegia n (%)
Right
Left
7 (47)
8 (53)
First/subsequent stroke n (%)
First
Second
 > 2
Unknown
9 (60)
3 (20)
2 (13)
1 (7)
Time since last stroke (years)
Mean (SD)
Min to max 
4.9 (1.9)
6 m – 22 y
Cause of stroke n (%)
Haemorrhage
Infarct
Unknown
5 (33)
9 (60)
1 (7)
SD: standard deviation.
Table III. Distance walked in 4 min and maximum walking speed over one complete circuit (20 m) with and without stimulation, at the 90 day and 
final assessments.
Baseline (n = 15)
NS
90 days (n = 13) Final (n = 13)
NS S NS S
Distance walked (m) 
Mean (SD)
Min to max
117.3 (46.7)
34–184
115.4 (49.3)
40–189
124.9 (47.0)
54–194
131 (51.5)
43–203
142.9 (49.3)
59–199
Max speed (m/sec)
Mean (SD)
Min to max
0.50 (0.20)
0.15–0.80
0.51 (0.22)
0.19–0.83
0.55 (0.20)
0.25–0.83
0.58 (0.23)
0.18–0.87
0.66 (0.22)
0.25–0.87
NS: not stimulated; S: stimulated; SD: standard deviation.
were experiencing problems with the wireless communication 
between the foot switch and the stimulator; this problem was 
resolved by a small redesign of the control unit.
Descriptive statistics for the maximum speed of walking and 
the distance walked in 4 minutes are shown in Table III at each 
time point for all available cases (15 at baseline, 13 at the 90 
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in one case wound healing was delayed. No serious device-
related adverse events were reported. There were no changes 
in nerve conduction velocity related to the nerve cuff. Table V 
shows the pre- and post-operative conduction velocities for 
each participant and each nerve branch tested. Conduction 
velocity > 39 m/sec is considered normal in the nerves tested 
(16). In 12 out of 15 subjects all assessments of conductance 
velocity in n. peroneus profundus, derivate m. extensor digi-
torum brevis and derivate m. tibialis anterior and n. peroneus 
superficialis were normal. In 3 subjects (3, 11, 15) the conduc-
tance velocity of n. profundus to m. extensor digitorum brevis 
was reduced distally in the lower leg pre-operatively, but these 
participants experienced no further reduction post-operatively. 
Although most participants showed change in conduction 
velocity, none were considered clinically relevant and none 
fell outside normal range.
DISCUSSION
The ActiGait drop foot stimulator has been evaluated in terms 
of safety (16) and performance, and results suggest that it may 
be a safe and feasible way of improving walking in people who 
have a drop foot as a result of a stroke. As with surface systems 
reported previously in the literature, our results show a similar 
improvement in maximum walking speed over time (19%). At 
the final assessment, however, 91% of participants who had a 
functioning system reported using the system regularly, com-
pared with 53% using a comparable surface system (7). The 
only implanted system reported in the literature recently (11) 
showed slightly better results than ours, but was only reported 
on 2 patients. In this study we did not measure the selectivity 
achieved by individual control of the 4 stimulation channels, 
but in all cases it was possible to achieve satisfactory ankle 
movement during walking. Walking appears to continue to 
improve beyond 3 months, as shown by greater improvement 
both with and without stimulation at the final assessment com-
pared with baseline and 90 days, in both maximum walking 
speed and distance walked in 4 min.
Although this study recruited participants from a chronic 
stroke population, evidence for continuing change, either im-
provement or deterioration, and especially in gait parameters, 
beyond 12 months from stroke (17) means that the interval 
between assessments is important. Subsequent trials should 
Table IV. Long-term therapeutic and orthotic effects of stimulation in distance walked in 4 min and maximum walking speed over one complete 
circuit (20 m): n = 13. Figures are mean difference (95% CI), paired t-test p-value.
Mean diff (95% CI) p Mean diff (95% CI) p
Long-term effects of stimulation 90 days (S) – baseline (NS) Final (S) – baseline (NS)
Distance walked (m) 9.23 (–0.67, 19.13) 0.065 16.23 (2.03, 30.43) 0.028
Max speed (m/sec) 0.05 (0.00, 0.10) 0.041 0.10 (0.03, 0.17) 0.008
Long-term therapeutic effects of stimulation 90 days (NS) – baseline (NS) Final (NS) – baseline (NS)
Distance walked (m) –0.31 (–10.57, 9.96) 0.949 4.77 (–8.42, 17.96) 0.446
Max speed (m/sec) 0.01 (–0.04, 0.06) 0.634 0.04 (–0.04, 0.11) 0.282
Orthotic effect of stimulation 90 days (S – NS) Final (S – NS)
Distance walked (m) 9.54 (2.53, 16.55) 0.012 11.46 (–0.12, 23.04) 0.052
Max speed (m/sec) 0.04 (0.01, –0.07) 0.023 0.07 (0.02, 0.11) 0.011
CI: confidence interval.
Table V. Conduction velocity (m/sec) of n. peroneus profundus, deriviate to m. extensor digitorum brevis (m.EDB) and m. tibialis anterior (m.TA) 
and n. peroneus superficialis (n.PS) pre- and > 90 days post-surgery.
ID
m.EDB m.TA n.PS
Pre-surgery Post-surgery Pre-surgery Post-surgery Pre-surgery Post-surgery
1 48 55 66 71 62 77
2 40 41 55 63 57 59
3 36* 37* 46 52 58 63
4 43 42 72 100 65 86
5 47 51 75 63 87 83
6 45 49 75 80 90 88
7 45 47 64 64 60 56
8 49 47 61 55 61 61
9 40 49 58 58 52 52
10 50 51 52 52 52 52
11 38* 41 57 50 50 52
12 48 54 73 92 83 80
13 47 44 55 58 58 58
14 50 49 77 78 76 79
15 34* 37* 78 77 80 66
*Abnormally reduced nerve conduction velocity.
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therefore not only include a control group, but should also 
ensure that assessments are performed at the same intervals 
for all participants.
Two participants (who required re-implantation with a smal-
ler cuff-size) did not have a functioning device at the time of 
the 90 day assessment, did not have assessments made and 
could not be included in the analysis at that time point. Both 
participants were, however, included in the final assessment 
following re-implantation. The trial sample at each assessment 
was therefore not the same and because of the small sample 
this may have influenced the results. Assessments with parti-
cipants who experienced footswitch communication problems 
at the 90 day assessment and whose walking was therefore 
suboptimal were included in the analysis following an ITT 
approach. This trial has provided an opportunity to resolve 
both these problems so that we are now in a good position 
to perform a larger trial incorporating ITT analysis with all 
participants at follow-up.
Because this was a phase II trial we did not specifically define 
efficacy comparisons as primary and secondary. Nevertheless, 
there were expectations that the long-term effect of stimulation 
and the orthotic effects would show worthwhile improvements, 
with no expectation of long-term therapeutic benefit. To take 
account of the testing at 2 time-points Bonferroni corrections 
to the significance levels were used. Although the findings 
concerning efficacy are encouraging, the study was essentially 
exploratory and we would like to see the results replicated in 
a larger randomized controlled trial.
Our experience in conducting this trial has led us to consider 
the relevance of measurements taken in the artificial environ-
ment of a physiotherapy department, as they may not reflect 
the actual benefit that patients regard as being important in 
their everyday life. Discussions with participants identified 
individual’s different reasons for using the system – each 
participant had their own expectations and goals, although 
increased confidence in walking seemed to be predominant. It 
may therefore be more appropriate in future investigations to 
use a patient-centred outcome measure, such as the Canadian 
Occupational Performance Measure (COPM) (18–20), which 
has recently been shown to be sensitive to changes following 
use of a surface drop-foot system with patients suffering from 
multiple sclerosis (21). In addition to this, as well as record-
ing walking parameters in a controlled environment, we are 
considering using an activity monitor to record activity in the 
everyday environment over a period of 7 days. 
Participants who took part in the trial were younger than the 
average stroke population, without co-morbidity and at least 6 
months post-stroke – it may be that this is a more active sub-
population, for whom the problem of drop-foot has persisted, 
who are most appropriate for this intervention. The system may 
also be feasible for use in other upper motor neurone lesions, 
such as multiple sclerosis and incomplete spinal cord injury.
In conclusion, the ActiGait drop foot stimulator is a safe and 
feasible way of correcting drop foot in stroke patients. There were 
no incidences of clinically relevant reduction in nerve conduction 
velocity due to the implant; therefore it is concluded that the risk 
of nerve damage due to the surgical procedures and the encircling 
of the nerve by the cuff-electrode is minimal. Acceptance in this 
group of patients was better than reported in a previous study 
of a surface system. Based on the experience and results of this 
phase II trial, we recommend a larger randomized controlled trial 
be carried out incorporating patient centred objective outcome 
measures that reflect the perceived benefit of the device.
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